Notably, Proteolysis-targeting chimaeras (PROTACs)-induced knockdown of SMARCA4 exhibits pronounced anti-proliferative effects in AML cell lines [48], indicating that targeted degradation of BRG1 is a possible SMARCA4-dependent treatment strategy for cancer. The gene discussed is SMARCA4; the disease is acute myeloid leukemia.